Isofol Medical AB (publ) (OM: ISOFOL)
Health Care · Biotechnology · SE
Skr0.83
+1.10% today · -5.3% 1Y
Isofol Medical AB (publ) (OM: ISOFOL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.75M and employs 6 people.
Over the last twelve months the share price has lost 5.3%, trading between 0.55 and 0.99.
Tweenvest scores Isofol Medical AB (publ) across four factors: quality 26/100. Its strongest factor is quality.
ISOFOL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.75M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.22
- Dividend yield
- —
- Beta (5Y)
- 1.03
- 52-week high
- Skr0.99
- 52-week low
- Skr0.55
- Avg volume (3M)
- —
- Shares outstanding
- 320.49M
- Employees
- 6
- Next earnings
- —
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
- ISIN
- SE0009581051
- Founded
- 2008
- Listed since
- Apr 4, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.